Neurocrine Biosciences Non-GAAP EPS of $1.88 misses by $0.42, revenue of $805.5M beats by $16.2M
Source: SeekingAlpha
2026-02-11 16:03:08 ET
More on Neurocrine Biosciences
- Neurocrine Biosciences, Inc. (NBIX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Neurocrine Biosciences, Inc. (NBIX) Discusses Progress and Strategy in Neurology and Obesity R&D Programs Transcript
- Neurocrine Biosciences, Inc. (NBIX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
- Neurocrine Biosciences Q4 2025 Earnings Preview
- Neurocrine's Ingrezza fails in phase 3 trial for dyskinetic cerebral palsy
Read the full article on Seeking Alpha
For further details see:
Neurocrine Biosciences Non-GAAP EPS of $1.88 misses by $0.42, revenue of $805.5M beats by $16.2M
Neurocrine Biosciences Inc.
NASDAQ: NBIX
NBIX Trading
1.45% G/L:
$129.92 Last:
272,259 Volume:
$130.42 Open:
NBIX Latest News
March 06, 2026 05:00:00 pm
BetterInvesting(TM) Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX)
February 26, 2026 09:35:00 am
From Lab to Clinic: Five CNS Companies Advancing Neuroscience Treatments
NBIX Stock Data
$13,828,183,256
94,919,824
0.84%
315
N/A
Pharmaceuticals
Healthcare
US
San Diego
